J&J/Genmab’s Darzalex Leads Way For Anti-CD38 Antibodies in Myeloma
This article was originally published in The Pink Sheet Daily
Executive Summary
Speedy even by the standards of accelerated approval, FDA’s clearance of first-in-class daratumumab in salvage setting gives hope for broader ambitions in myeloma and beyond.